MedTrace Logo

The Impact of Exercise With Blood Flow Restriction: Sex and Age Differences

NCT05615831 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-12-13

No results posted yet for this study

Summary

The primary objective is to investigate whether six weeks of resistance training, in combination with blood flow restriction, produces a different adaptation in fat-free mass between males and females that are not physically active. The secondary objective is to compare changes in physical function, physical performance, and blood biomarkers between males and females following resistance training and blood flow restriction.

Conditions

  • Physical Activity

Interventions

BEHAVIORAL

Resistance Training with Blood flow restriction

Participants will perform six weeks of blood flow restriction (60% occlusion) combined with resistance training at 30% of 1RM. The intervention comprises five exercises: incline chest press, seated row, leg press, knee extension, and knee flexion. The protocol is as follows: 30 repetitions followed by three sets of 15 repetitions for a total of four sets and 75 repetitions per exercise. There will be a one-minute recovery between sets where the cuffs remain inflated and a four-minute recovery between exercises where the cuffs will be deflated.

Sponsors & Collaborators

  • Public Health Agency of Canada (PHAC)

    collaborator OTHER_GOV

  • University of New Brunswick

    lead OTHER

Principal Investigators

  • Martin Senechal, PhD · University of New Brunswick

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-11-22
Completion
2023-11-22

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05615831 on ClinicalTrials.gov